Related Experiment Videos
Macrophage activation syndrome in the acute phase of Kawasaki disease
Giuseppe A Latino1, Cedric Manlhiot, Rae S M Yeung
1Division of Cardiology, University of Toronto, The Hospital for Sick Children, Toronto, Ontario, Canada.
Abstract:
Rare cases of macrophage activation syndrome (MAS) occurring during the acute phase of Kawasaki disease (KD) have been reported. We sought to characterize, review treatment, and outcomes of KD patients with clinical features of MAS. Medical histories of patients treated for KD and MAS between January 2001 and March 2008 were reviewed. Of 638 KD patients seen, 12 (1.9%) had additional clinical findings usually associated with MAS; 7 of them were males older than 5 years (6.1%; odds ratio: 6.8, P=0.002). Clinically, 9 patients had at least 4 of 5 KD clinical signs, and all patients had prolonged fever beyond initial intravenous immunoglobulin treatment. Hepatosplenomegaly, cytopenia in two or more cell lines, hypertriglyceridemia and/or hypofibrinogenemia, and increased D-dimers were seen in 11 patients. Hyperferritinemia and elevated hepatic enzymes were seen in all patients. Four patients had biopsy-proven evidence of hemophagocytosis. All but 2 patients met at least 5 of 8 criteria necessary for MAS diagnosis. Treatment beyond the standard KD protocol (aspirin + intravenous immunoglobulin) was necessary in all but 1 patient. All patients eventually recovered with no long-term sequelae. A high index of suspicion for clinical features associated with MAS is warranted for KD patients to provide appropriate and timely treatment.
Insights
Rare cases of macrophage activation syndrome (MAS) in Kawasaki disease (KD) patients were studied. Prompt treatment beyond standard protocols led to full recovery without long-term effects, highlighting the need for early MAS detection in KD.
Area of Science:
- Pediatrics
- Rheumatology
- Immunology
Background:
- Macrophage activation syndrome (MAS) is a rare but severe complication.
- Kawasaki disease (KD) is an acute febrile vasculitis primarily affecting young children.
- The co-occurrence of MAS in KD presents diagnostic and therapeutic challenges.
Purpose of the Study:
- To characterize the clinical features of KD patients presenting with MAS.
- To review the treatment strategies and outcomes for these patients.
- To emphasize the importance of early recognition and intervention for MAS in KD.
Main Methods:
- Retrospective review of medical histories of KD patients diagnosed with MAS between January 2001 and March 2008.
- Analysis of clinical signs, laboratory findings, and diagnostic criteria for MAS.
- Evaluation of treatment protocols and patient outcomes.
Main Results:
- 1.9% of 638 KD patients exhibited MAS features.
- MAS was more common in males older than 5 years (OR: 6.8, P=0.002).
- Key findings included prolonged fever, hepatosplenomegaly, cytopenia, hypertriglyceridemia, hypofibrinogenemia, elevated D-dimers, hyperferritinemia, and elevated liver enzymes. Hemophagocytosis was confirmed in 4 patients. Most met MAS diagnostic criteria.
- Treatment beyond standard KD care was required for most patients, leading to complete recovery without sequelae.
Conclusions:
- KD patients with MAS require heightened clinical suspicion for timely diagnosis.
- Aggressive treatment beyond standard KD protocols is often necessary for favorable outcomes.
- Early detection and management of MAS in KD can prevent severe complications and ensure full recovery.
Related Concept Videos
Acute Coronary Syndrome II: Pathophysiology and Clinical Manifestations
Acute Inflammation II: Cellular Phase
Acute Inflammation I: Inflammatory Response
Chronic Inflammation: Introduction
Inflammation
Rheumatic Heart Disease I: Introduction